New Version of CRISPR Corrects RNA Defects Linked to Huntington’s, ALS

News   Aug 15, 2017 | Original story from University of California, San Diego

 
New Version of CRISPR Corrects RNA Defects Linked to Huntington’s, ALS

These are muscle cells from a patient with myotonic dystrophy type I, untreated (left) and treated with the RNA-targeting Cas9 system (right). The MBNL1 protein is in green, repetitive RNA in red and the cell’s nucleus in blue. MBNL1 is an important RNA-binding protein and its normal function is disrupted when it binds repetitive RNA. In the treated cells on the right, MBNL1 is released from the repetitive RNA. Credit: UCSD

 
 
 

RELATED ARTICLES

Neuropeptide Y Y1 Receptor Structure Solved, Offers New Opportunities for Anti-obesity Drug Discovery

News

Scientists solve the crystal structure of Neuropeptide Y Y1 Receptor, offering new opportunities for anti-obesity drug discovery.

READ MORE

Crystal Structure of Neuropeptide 1 Receptor Solved, Providing Therapeutic Angle For Obesity Treatment

News

An international team has uncovered the potential to beat obesity at the cellular level, characterizing for the first time a complex, little-understood receptor type that, when activated, shuts off hunger.

READ MORE

Quadruple Patch-Clamp Recording In Vivo Reveals Novel Cortical Circuit Communication Logic

News

Researchers patched 4 cells simultaneously in the neocortex and discovered a novel type of functional circuit logic.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE